ALT 0.00% 0.1¢ analytica limited

Ann: Investor Presentation , page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 23,919 Posts.
    lightbulb Created with Sketch. 752
    Fantastic investor presentation

    - Taiwan regulatory approval moving quicker than expected, with sales potentially happening before the end of the year. Taiwan distributors are pushing hard to get access to China and other Asian markets. ALT making them secure sales in Taiwan first.

    - High level board meeting in Brazil in next week(s) where expected to sign distribution agreement. Brazil regulatory approval progressing in background with sales potentially before end of the year also.

    - 2 majors in US & EUR closely watching outcome of Brazil.

    - Explained how burette is a slow process given liaising with majors, red tape, hospital officers with vested interests etc. Has been delays in sales due to redesigning of the device to incorporate autoflush feature. Confident if they secure Brazil (with Taiwan already in the bag), will make enough noise for US & EUR to push the button.

    - Drew comparisons to shareprice rally of ISN with respect to PeriCoach being mobile health device. Incontinence market several fold the asthma market and similar exponential revenue potential.

    - Attraction of Pericoach is no barrier to entry (hospitals, vested interests etc), no comparable product, purely a marketing play and directly addresses a huge need and grows the market. Major launch in next month and a bit.

    - Potential for it to be included on medicare levy or private health funds given $ savings in later life not having to use pads.

    - Assume very conservative profit of $10 per unit per month ($120 per year compared to forecasted $150-200), 10,000 units sold domestically would see $1.2M revenue and them cashflow positive.

    - Planning a production run of 50,000 units next year and confident to sell them domestically as pure marketing play, already have large amount of doctors, clinicians and physio's onboarding supporting.

    - Incentive for heath professionals to recommend as they can monitor patient and get several repeat visits to follow up on progress and results.

    - At some stage, plan to send product to nameplate such as Whoopie Goldberg who openly spoke about incontinence.

    - Potentially by end of this year expect to have sales in Brazil and Taiwan, with PeriCoach sales commencing early next year.



 
watchlist Created with Sketch. Add ALT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.